Literature DB >> 11486286

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

M M McNeil1, S L Nash, R A Hajjeh, M A Phelan, L A Conn, B D Plikaytis, D W Warnock.   

Abstract

To determine national trends in mortality due to invasive mycoses, we analyzed National Center for Health Statistics multiple-cause-of-death record tapes for the years 1980 through 1997, with use of their specific codes in the International Classification of Diseases, Ninth Revision (ICD-9 codes 112.4-118 and 136.3). In the United States, of deaths in which an infectious disease was the underlying cause, those due to mycoses increased from the tenth most common in 1980 to the seventh most common in 1997. From 1980 through 1997, the annual number of deaths in which an invasive mycosis was listed on the death certificate (multiple-cause [MC] mortality) increased from 1557 to 6534. In addition, rates of MC mortality for the different mycoses varied markedly according to human immunodeficiency virus (HIV) status but were consistently higher among males, blacks, and persons > or =65 years of age. These data highlight the public health importance of mycotic diseases and emphasize the need for continuing surveillance.

Entities:  

Mesh:

Year:  2001        PMID: 11486286     DOI: 10.1086/322606

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  160 in total

Review 1.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Oxidative stress survival in a clinical Saccharomyces cerevisiae isolate is influenced by a major quantitative trait nucleotide.

Authors:  Stephanie Diezmann; Fred S Dietrich
Journal:  Genetics       Date:  2011-04-21       Impact factor: 4.562

3.  Emerging opportunistic fungal infections: where are we heading?

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2003-12       Impact factor: 1.798

4.  What's New in Antifungals?

Authors:  John M. Valgus
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

5.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

Review 6.  Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.

Authors:  Rami Sherif; Brahm H Segal
Journal:  Curr Opin Pulm Med       Date:  2010-05       Impact factor: 3.155

7.  New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis.

Authors:  Christophe Duret; Nathalie Wauthoz; Thami Sebti; Francis Vanderbist; Karim Amighi
Journal:  Pharm Res       Date:  2012-05-30       Impact factor: 4.200

Review 8.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 9.  Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Assessment of Aspergillus-specific T cells for diagnosis of invasive aspergillosis in a leukemic child with liver lesions mimicking hepatosplenic candidiasis.

Authors:  Leonardo Potenza; Patrizia Barozzi; Giulio Rossi; Giovanni Palazzi; Daniela Vallerini; Giovanni Riva; Monica Cellini; Monica Morselli; Francesco Volzone; Claudia Venturelli; Chiara Quadrelli; Luciana Di Pancrazio; Maria Carmen Cano; Paolo Paolucci; Giuseppe Torelli; Mario Luppi
Journal:  Clin Vaccine Immunol       Date:  2008-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.